Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioStar merger makes Cortech instant player in in vitro diagnostics market.

This article was originally published in The Gray Sheet

Executive Summary

CORTECH SHIFTING STRATEGIC FOCUS TOWARD POINT-OF-CARE DIAGNOSTICS through acquisition of privately held BioStar, valued at about $18.7 mil. Under a definitive merger agreement announced Dec. 23, Cortech would trade 28.5 mil. new shares of common stock for all of BioStar; Cortech stock closed at 21/32 on Dec. 22. "We believe that this merger will enable us to create one of the premier point-of-care diagnostics companies in the country," BioStar President and CEO Teresa Ayers remarked.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel